FBIO - Fortress Biotech, Inc.
| Previous Close | 1.2500 |
| Open | 1.2700 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 3100 |
| Day's Range | 1.2100 - 1.2800 |
| 52 Week Range | 0.4900 - 2.5900 |
| Volume | 34,520 |
| Avg. Volume | 330,801 |
| Market Cap | 88.374M |
| Beta (3Y Monthly) | 3.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1190 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- GlobeNewswire
Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma
NEW YORK, Oct. 10, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- GlobeNewswire
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC)40% objective response rate observed in non-small cell lung cancerWell-tolerated safety profile.
- GlobeNewswire
Mustang Bio to Participate in October 2019 Investor Conferences
NEW YORK, Sept. 26, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.
- GlobeNewswire
Fortress Biotech to Present at October 2019 Investor Conferences
Fortress Biotech, Inc. (FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences.
- GlobeNewswire
Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 26, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,.
- GlobeNewswire
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and is beginning to treat its first patients in a Phase 1 clinical trial of MB-105, a prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) T technology, for the treatment of prostate cancer. MB-105 was developed in the laboratory of Saul Priceman, Ph.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation and a scientist in the T Cell Therapeutics Research Laboratory led by Stephen Forman, M.D., leader of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation.
- GlobeNewswire
Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
NEW YORK, Sept. 16, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,.
- Simply Wall St.
Investors Who Bought Fortress Biotech (NASDAQ:FBIO) Shares Three Years Ago Are Now Down 24%
Fortress Biotech, Inc. (NASDAQ:FBIO) shareholders will doubtless be very grateful to see the share price up 42% in the...
- GlobeNewswire
Mustang Bio to Present at Scientific Conferences in September 2019
NEW YORK, Sept. 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.
- GlobeNewswire
Checkpoint Therapeutics to Present at September 2019 Investor Conferences
NEW YORK, Sept. 04, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,.
- GlobeNewswire
Mustang Bio to Present at September 2019 Investor Conferences
NEW YORK, Aug. 29, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Taronis Technologies (NASDAQ: TRNX ) shares ...
- GlobeNewswire
Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license agreement with CSL Behring for the Cytegrity™ stable producer cell line developed and used by St. Jude Children’s Research Hospital (“St. Jude”). Cytegrity™ stable producer cell line will be used to produce the viral vector for Mustang Bio’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID).
- GlobeNewswire
Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA
Mustang Bio, Inc. (MBIO) and St. Jude Children’s Research Hospital have announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). Mustang, a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and St. Jude, the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases, established a partnership to continue development of the lentiviral gene therapy in August 2018.
- GlobeNewswire
Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors
Fortress Biotech, Inc. (FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury & Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies.
- GlobeNewswire
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 14, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
- GlobeNewswire
Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
NEW YORK, Aug. 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- GlobeNewswire
Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 09, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.
- GlobeNewswire
Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- GlobeNewswire
Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 08, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,.
- GlobeNewswire
FDA Clears IND for Mustang Bio’s MB-102 (CD123 CAR T)
NEW YORK, Aug. 05, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- GlobeNewswire
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Ms. Garrett Ingram has been appointed to its Board of Directors. Ms. Ingram joined Cipla USA, Inc. (“Cipla”) in July 2019 as Chief Commercial Officer, Specialty Hospital Business, U.S. to lead the transformation of the current and future specialty branded platforms.
- GlobeNewswire
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia
NEW YORK, July 24, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- Simply Wall St.
Have Insiders Been Selling Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- GlobeNewswire
Checkpoint Therapeutics Added to Russell 2000® Index
NEW YORK, July 01, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,.
